-
公开(公告)号:US20120219542A1
公开(公告)日:2012-08-30
申请号:US13497451
申请日:2010-09-22
申请人: Jochen Reiser
发明人: Jochen Reiser
IPC分类号: A61K39/395 , C12Q1/37 , G01N33/48 , C12N9/50 , G01N21/64 , C07K14/47 , A61K38/02 , C07H21/00 , C07K2/00 , C07K16/18 , C07K14/00 , C12Q1/02 , A61K31/7088
CPC分类号: A61K38/4873 , A61K31/198 , G01N33/5044 , G01N2800/34
摘要: Compositions are directed to the treatment of kidney diseases in a cell-specific manner. Methods of treating kidney diseases comprise the use of the compositions. Assays for identification of further compounds are provided. Biomarkers for predisposition to kidney diseases and diagnosis are identified.
摘要翻译: 组合物以细胞特异性方式用于治疗肾脏疾病。 治疗肾脏疾病的方法包括使用该组合物。 提供了用于鉴定其它化合物的试验。 鉴定了潜在的肾脏疾病和诊断的生物标志物。
-
公开(公告)号:US20100221317A1
公开(公告)日:2010-09-02
申请号:US12693858
申请日:2010-01-26
申请人: Jochen Reiser , Sanja Sever
发明人: Jochen Reiser , Sanja Sever
IPC分类号: A61K9/127 , A61K31/7088 , A61K38/16 , C07H21/04 , A61P25/28 , A61P35/00 , A61P35/04 , A61P13/12 , A61P9/00 , A61P3/10 , C12N15/63 , C12N5/10 , C12Q1/34
CPC分类号: A61K38/46 , A61K38/177 , A61K38/55 , C12Y306/05005
摘要: This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer.
摘要翻译: 本发明一般涉及组织蛋白酶或dynamin介导的疾病如蛋白尿,癌症和认知疾病及相关产品的治疗。 还提供了诊断和其他测定,以及足细胞细胞基因转移的方法。
-
公开(公告)号:US07670817B2
公开(公告)日:2010-03-02
申请号:US11594003
申请日:2006-11-07
申请人: Jochen Reiser , Sanja Sever
发明人: Jochen Reiser , Sanja Sever
CPC分类号: A61K38/46 , A61K38/177 , A61K38/55 , C12Y306/05005
摘要: This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer.
摘要翻译: 本发明一般涉及组织蛋白酶或dynamin介导的疾病如蛋白尿,癌症和认知疾病及相关产品的治疗。 还提供了诊断和其他测定,以及足细胞细胞基因转移的方法。
-
公开(公告)号:US20070197438A1
公开(公告)日:2007-08-23
申请号:US11594003
申请日:2006-11-07
申请人: Jochen Reiser , Sanja Sever
发明人: Jochen Reiser , Sanja Sever
CPC分类号: A61K38/46 , A61K38/177 , A61K38/55 , C12Y306/05005
摘要: This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer.
摘要翻译: 本发明一般涉及组织蛋白酶或dynamin介导的疾病如蛋白尿,癌症和认知疾病及相关产品的治疗。 还提供了诊断和其他测定,以及足细胞细胞基因转移的方法。
-
公开(公告)号:US20110236397A1
公开(公告)日:2011-09-29
申请号:US13127839
申请日:2009-11-06
申请人: Jochen Reiser , Brian Adair
发明人: Jochen Reiser , Brian Adair
IPC分类号: A61K39/395 , A61K38/48 , A61K31/7088 , A61K38/02 , A61K38/43 , C12Q1/37 , C12Q1/02 , C07K14/47 , C12N15/63 , C07K16/18 , C12N9/00 , C12N9/64 , C12N9/14 , A61P13/12 , A61P3/10 , A61P7/00 , A61P35/00 , A61P31/00
CPC分类号: C07K16/18 , A61K38/4873 , C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/14 , C12N2310/16 , C12Y304/23005 , G01N33/5044
摘要: Compositions which specifically block cathepsin L function in podocytes, compositions which protect cytoskeletal adaptor protein (CD2AP) for degradation, compositions which modulate expression or function of cytoskeletal adaptor protein (CD2AP), protect against renal diseases or disorders. Methods of treatment in vivo involve use of one or more compositions.
摘要翻译: 特异性阻断组织蛋白酶L在足细胞中功能的组合物,保护细胞骨架衔接蛋白(CD2AP)进行降解的组合物,其调节细胞骨架衔接蛋白(CD2AP)的表达或功能的组合物,可防止肾脏疾病或病症。 体内治疗方法涉及使用一种或多种组合物。
-
公开(公告)号:US09867923B2
公开(公告)日:2018-01-16
申请号:US14116470
申请日:2012-05-09
申请人: Jochen Reiser
发明人: Jochen Reiser
CPC分类号: A61M1/3486 , A61K35/16 , A61K38/177 , A61M1/3496 , A61M1/362 , A61M1/3672 , A61M1/3679 , A61M1/3687 , C07K14/70596 , G01N33/6872
摘要: Focal segmental glomerulosclerosis (FSGS) is a common cause of proteinuric kidney disease, which comprises both native and transplanted kidneys. Treatment was limited in the past due to the complicated pathogenesis of FSGS, including previously unidentified serum factors. Here, serum soluble urokinase receptor (suPAR) is reported to be elevated in FSGS patients but not in patients with other primary glomerular diseases. Higher pre-transplantation suPAR levels are associated with risk for FSGS recurrence in kidney grafts. Renal disease only develops when suPAR sufficiently activates podocyte β3 integrin. Thus, disease pathogenesis can be stopped or slowed by ex vivo removal of suPAR from a subject's circulation. Removal may be measured by comparing the level (e.g., amount or concentration) of suPAR before and after such treatment.
-
公开(公告)号:US09345739B2
公开(公告)日:2016-05-24
申请号:US12740090
申请日:2008-11-07
申请人: Jochen Reiser
发明人: Jochen Reiser
IPC分类号: A61K39/395 , G01N33/53 , A61K38/06 , A61K31/506 , A61K38/07 , A61K38/12 , C07K16/28 , A61K39/00
CPC分类号: A61K38/12 , A61K9/0019 , A61K31/506 , A61K38/06 , A61K38/07 , A61K38/08 , A61K2039/505 , C07K16/2848 , C07K2317/55 , G01N33/6893 , G01N2333/70557 , G01N2800/347
摘要: The present invention is directed to methods of treating proteinuric diseases by the administration of avβ3 integrin inhibitors.
摘要翻译: 本发明涉及通过施用av&bgr 3整联蛋白抑制剂治疗蛋白尿性疾病的方法。
-
公开(公告)号:US20120213775A1
公开(公告)日:2012-08-23
申请号:US13402689
申请日:2012-02-22
申请人: Jochen Reiser
发明人: Jochen Reiser
IPC分类号: A61K39/395 , A61P13/12 , C07K16/28
CPC分类号: C07K16/2839 , A61K2039/505 , C07K2317/21
摘要: Compositions for the treatment of renal diseases and disorders utilize agents which inhibit alphaV integrin molecules in vivo. Methods of treatment include use of these agents in the prevention and treatment of proteinuria, progressive glomerular disease and glomerular disease amongst others.
摘要翻译: 用于治疗肾脏疾病和病症的组合物利用在体内抑制αV整联蛋白分子的药剂。 治疗方法包括使用这些药物预防和治疗蛋白尿,进行性肾小球疾病和肾小球疾病等。
-
9.
公开(公告)号:US20100297139A1
公开(公告)日:2010-11-25
申请号:US12740090
申请日:2008-11-07
申请人: Jochen Reiser
发明人: Jochen Reiser
IPC分类号: A61K39/395 , A61K38/02 , A61K38/06 , A61P13/12 , A61P37/06 , A61P7/00 , A61P31/04 , A61P31/12 , A61P29/00
CPC分类号: A61K38/12 , A61K9/0019 , A61K31/506 , A61K38/06 , A61K38/07 , A61K38/08 , A61K2039/505 , C07K16/2848 , C07K2317/55 , G01N33/6893 , G01N2333/70557 , G01N2800/347
摘要: The present invention is directed to methods of treating proteinuric diseases by the administration of avβ3 integrin inhibitors.
摘要翻译: 本发明涉及通过施用av&bgr 3整联蛋白抑制剂治疗蛋白尿性疾病的方法。
-
公开(公告)号:US20220135669A1
公开(公告)日:2022-05-05
申请号:US17278959
申请日:2019-09-30
申请人: Jochen REISER , Salim HAYEK , Arshed A. QUUYUMI
发明人: Jochen REISER , Salim HAYEK , Arshed A. QUUYUMI
IPC分类号: C07K16/28 , A61P13/12 , C07K14/705 , G01N33/68
摘要: Methods and compositions for treating acute kidney injury in a subject are provided. The methods include measuring or having measured a level of soluble urokinase plasminogen activator receptor (suPAR) in a biological sample from the subject, determining or having determined the level of suPAR in the sample compared to a control suPAR level, and administering a therapeutically effective amount of an agent that antagonizes soluble urokinase plasminogen activator receptor (suPAR) to the subject having an elevated level of suPAR relative to the control suPAR level.
-
-
-
-
-
-
-
-
-